

**Supplementary Information for “Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors”**

Sho Iketani<sup>1,2</sup>, Farhad Forouhar<sup>3</sup>, Hengrui Liu<sup>4</sup>, Seo Jung Hong<sup>5</sup>, Fang-Yu Lin<sup>6</sup>, Manoj S. Nair<sup>1</sup>, Arie Zask<sup>7</sup>, Yaoxing Huang<sup>1</sup>, Li Xing<sup>6</sup>, Brent R. Stockwell<sup>4, 7\*</sup>, Alejandro Chavez<sup>5\*</sup>, David D. Ho<sup>1\*</sup>

<sup>1</sup> Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY 10032, USA

<sup>2</sup> Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA

<sup>3</sup> Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA

<sup>4</sup> Department of Chemistry, Columbia University, New York, NY 10027, USA


<sup>5</sup> Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA

<sup>6</sup> WuXi AppTec, Cambridge, MA 02142, USA

<sup>7</sup> Department of Biological Sciences, Columbia University, New York, NY 10027, USA

\* Corresponding authors

**Supplementary Fig 1. Cytotoxicity of compounds in Vero-E6 cells.** Vero-E6 cells were incubated with serial dilutions of each compound for 48 h and then tested for cytotoxicity. Data are shown as mean  $\pm$  s.e.m. for three experimental replicates.



**Supplementary Table 1. Bacterial codon optimized SARS-CoV-2 3CL protease sequence used in this study.**

TCAGGGTTCCGCAAGATGGCGTTTCCGTCGGGAAAGGTGGAAGGCTGCATGGTCCAGGTGAC  
CTGCGGCACTACGACGTTGAATGGCCTGTGGTTAGACGATGTCGTATATTGCCCGCGTCACGT  
CATTTGTACGTCAGAGGATATGCTGAATCCCAACTACGAGGACTTGTTAATCCGCAAAAAGTAAC  
CACAACCTTTCTGGTGCAAGCAGGGAACGTACAGCTGCGCGTGATCGGGCACTCGATGCAGAAC  
TGC GTTCTCAAAC T GAAAGTAGACTGCAAACCCCAAACGCCGAAATACAAATTCGTCCGTA  
TCCAGCCGGGCCAAACCTTCTCCGTTTTGGCGTGCTATAACGGGAGCCCCTCGGGCGTGTATC  
AGTGCGCGATGCGCCCGAACTTTACAATCAAAGGGTCGTTCTTGAACGGCAGTTGCGGAAGCG  
TGGGCTTCAATATCGACTACGATTGCGTTAGTTTCTGCTATATGCATCACATGGAGCTCCCGAC  
CGGCGTGACGCGCGGTACTGATCTTGAGGGGAATTTCTACGGGCCATTCGTAGATCGTCAGAC  
CGCGCAGGCGGCAGGGACCGATAACCACCATCACCGTGAACGTA CTGCGGTGGCTGTATGCAG  
CAGTGATCAACGGTGATCGCTGGTTCCTGAACCGCTTCACAACGACCCTCAACGATTTCAATTT  
AGTCGCCATGAAATATAACTACGAGCCCTTGACGCAGGATCACGTGGATATCCTCGGCCCGCT  
GAGTGCGCAGACGGGGATCGCGGTGCTGGACATGTGCGCGAGCCTGAAGGAGCTTTTACAGA  
ACGGCATGAACGGTGCCTACTATCTTAGGCAGCGCACTGCTGGAAGACGAGTTCACCCCGTTTCG  
ACGTAGTACGCCAGTGTAGCGGAGTAACCTTTCAGTGA

**Supplementary Table 2. Primers used for Sanger sequencing of the SARS-CoV-2 3CL protease bacterial expression vector.**

Name	Sequence
SI-AC018	TTGACAATTAATCATCGGCT
PAC3830	ATATAGCATGGCCTTTGCAG
PAC4378	GAGCTGCATGTGTCAGAGGT